Welcome to our dedicated page for MVIR news (Ticker: $MVIR), a resource for investors and traders seeking the latest updates and insights on MVIR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MVIR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MVIR's position in the market.
Rhea-AI Summary
Medivir AB announces positive clinical pharmacokinetic data on fostrox at EASL Liver Cancer Summit, showing dose linearity and encouraging safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB (MVIR) has announced changes in the number of shares and votes due to rights and directed issues, resulting in a total increase of 56,211,817 ordinary shares. The company now has a total of 112,917,968 shares, with 112,053,218 ordinary shares and 864,750 class C-shares. Each ordinary share entitles to one vote, while each class C-share entitles to one tenth of a vote.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB (MVIR) announces participation at the Redeye Fight Cancer Day, presenting updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) focused on liver cancer treatment. The company emphasizes its commitment to addressing high unmet medical needs in cancer therapy, leveraging collaborations and partnerships to drive drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Medivir AB (MVIR) presents updated data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma (HCC) at the ASCO GI Symposium. The data shows that fostrox + Lenvima remains tolerable with no unexpected safety events and continues to improve clinical benefit. The company plans to discuss final study design of the planned phase 2b study with accelerated approval intent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB (MVIR) has announced a directed issue of 7,547,170 new ordinary shares, resulting in approximately SEK 20 million before issue costs. The right to subscribe for shares in the Directed Issue belongs to Hallberg Management AB, controlled by Anders Hallberg. The subscription price is SEK 2.65 per share. The Directed Issue aims to provide additional capital for the development of the Company's drug candidate fostrox and to strengthen the Company's shareholder base. The board of directors considers it a positive move for the Company and its shareholders, following the completion of the Rights Issue in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR) announced improved clinical benefit with fostrox + Lenvima in treating advanced hepatocellular carcinoma (HCC). The overall response rate (ORR) increased to 25%, with a median time to progression of 5.1 months and >40% of patients still on treatment. The combination showed a good safety profile, with the longest running patient still on treatment after ~17 months with a sustained partial response. The phase 1b/2a study data will be presented at the ASCO GI Symposium, supporting the initiation of a registrational phase 2b study in second-line HCC in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR) announced the presentation of clinical pharmacokinetic data for fostroxacitabine bralpamide (fostrox) at the EASL Liver Cancer Summit. The data will support regulatory interactions and further development of fostrox in patients with hepatocellular carcinoma (HCC).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medivir AB (MVIR) Announces First Patient Dosed with TNG348, a Novel USP1 Inhibitor by Licensee Tango Therapeutics (TNGX) for the Treatment of HRD+ Cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
-
Rhea-AI Summary
Medivir AB (Nasdaq Stockholm: MVIR) announces improved durable clinical benefit in maturing data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma (HCC), measured by local review. Consistent anti-tumor activity, >75% of patients experiencing tumor shrinkage in target lesions, with 80% sustained disease control at 12 weeks. Longest running patient still on treatment after 16 months with sustained partial response. The company plans to initiate a registrational phase 2b study in second-line HCC in 2024. Additional data from the ongoing phase 1b/2a study will be presented at the ASCO Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco, USA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Medivir AB (MVIR) has signed an agreement with Lonza for the manufacture of a new GMP campaign of fostrox drug substance for the planned phase 2b to enable study drug availability by the end of 2024. This collaboration aims to ensure maximum momentum in the fostrox development program, with plans for accelerated approval after the planned phase 2b study. Based on promising clinical data for fostrox + Lenvima, the company is moving forward with an intent to initiate phase 2b study with accelerated approval. This development has the potential to become the first approved treatment option for patients that have progressed on the current first line standard of care, addressing high unmet medical need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
MVIR